Madame Bioscience PCL (BKK:MADAME)
Thailand · Delayed Price · Currency is THB 0.5800
-0.0100 (-1.69%)
Last updated: Mar 2, 2026, 4:29 PM ICT
Madame Bioscience PCL Income Statement
Financials in millions THB. Fiscal year is January - December.
Millions THB. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,478 | 2,123 | 2,302 | 2,228 | 1,862 | |
Revenue Growth (YoY) | -30.39% | -7.78% | 3.35% | 19.61% | 22.79% |
Cost of Revenue | 1,156 | 1,763 | 2,006 | 2,146 | 1,561 |
Gross Profit | 321.76 | 359.99 | 296.44 | 81.33 | 301.34 |
Selling, General & Admin | 479.06 | 338.05 | 484.03 | 511.38 | 415 |
Other Operating Expenses | -390.1 | -19.91 | -21.41 | -44.62 | -3.56 |
Operating Expenses | 88.95 | 318.01 | 462.7 | 466.76 | 411.44 |
Operating Income | 232.8 | 41.98 | -166.26 | -385.44 | -110.1 |
Interest Expense | -32.7 | -50.94 | -61.11 | -42.13 | -10.56 |
Interest & Investment Income | - | 0.36 | 1 | 0.54 | 0.1 |
Currency Exchange Gain (Loss) | - | 1.99 | 4.49 | 8.35 | 5.92 |
Other Non Operating Income (Expenses) | -5.04 | - | - | - | - |
EBT Excluding Unusual Items | 195.06 | -6.6 | -221.88 | -418.67 | -114.64 |
Impairment of Goodwill | - | - | -187.97 | -26.87 | -26.02 |
Gain (Loss) on Sale of Investments | - | -98.01 | - | - | - |
Gain (Loss) on Sale of Assets | -77.18 | 0.64 | 0.86 | 1.39 | 32.33 |
Asset Writedown | -67.97 | - | - | - | -103.9 |
Other Unusual Items | - | -225.96 | -0.66 | - | - |
Pretax Income | 49.92 | -329.94 | -409.66 | -444.07 | -187.53 |
Income Tax Expense | 3.5 | -0.76 | 2.8 | -5.99 | -21.27 |
Earnings From Continuing Operations | 46.41 | -329.18 | -412.45 | -438.08 | -166.26 |
Earnings From Discontinued Operations | - | 0.04 | -0.85 | 1.22 | -0.37 |
Net Income to Company | 46.41 | -329.14 | -413.31 | -436.86 | -166.63 |
Minority Interest in Earnings | -0.64 | -2.9 | 7.5 | 14.55 | 14.19 |
Net Income | 45.77 | -332.04 | -405.81 | -422.31 | -152.43 |
Net Income to Common | 45.77 | -332.04 | -405.81 | -422.31 | -152.43 |
Shares Outstanding (Basic) | 3,814 | 621 | 615 | 600 | 400 |
Shares Outstanding (Diluted) | 3,814 | 621 | 615 | 600 | 400 |
Shares Change (YoY) | 514.14% | 0.93% | 2.57% | 50.07% | 5.07% |
EPS (Basic) | 0.01 | -0.53 | -0.66 | -0.70 | -0.38 |
EPS (Diluted) | 0.01 | -0.54 | -0.66 | -0.70 | -0.38 |
Free Cash Flow | -1.77 | 211.62 | 32.37 | -307.46 | -304.86 |
Free Cash Flow Per Share | - | 0.34 | 0.05 | -0.51 | -0.76 |
Gross Margin | 21.77% | 16.96% | 12.88% | 3.65% | 16.18% |
Operating Margin | 15.75% | 1.98% | -7.22% | -17.30% | -5.91% |
Profit Margin | 3.10% | -15.64% | -17.63% | -18.96% | -8.19% |
Free Cash Flow Margin | -0.12% | 9.97% | 1.41% | -13.80% | -16.37% |
EBITDA | 329.89 | 110.97 | -81.76 | -309.71 | -35.37 |
EBITDA Margin | 22.32% | 5.23% | -3.55% | -13.90% | -1.90% |
D&A For EBITDA | 97.09 | 68.98 | 84.49 | 75.73 | 74.74 |
EBIT | 232.8 | 41.98 | -166.26 | -385.44 | -110.1 |
EBIT Margin | 15.75% | 1.98% | -7.22% | -17.30% | -5.91% |
Effective Tax Rate | 7.02% | - | - | - | - |
Revenue as Reported | - | - | - | 2,228 | 1,862 |
Advertising Expenses | - | 3.14 | 80.99 | 14.79 | 16.14 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.